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Effects of CPAP-respiration on markers of glucose
metabolism in patients with obstructive sleep apnoea
syndrome: a systematic review and meta-analysis
Effekte einer CPAP-Therapie auf Marker des Glukosestoffwechsels bei
Patienten mit obstruktivem Schlafapnoe-Syndrom: ein systematischer
Review mit Metaanalyse
Abstract
Background:ObstructiveSleepApnoeaSyndrome(OSAS)isacondition
ofobstruction,apneasandarousalswhilesleeping.Ithasbeensuggest-
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Ralph Möhler
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ed that OSAS independently influences glucose metabolism. The main
treatment for OSAS is continuous positive airways pressure (CPAP). Gabriele Meyer
2
Objectives: To assess the effects of CPAP on insulin resistance and
glucose metabolism. 1 Sana Hospital Oldenburg,
Diabetes Center, Oldenburg,
Germany
Search strategy: We searched Medline, Embase and the Cochrane
Controlled Trial Register (January 2010).
Selection criteria: We included randomised and non-randomised trials
comparing CPAP with inactive control or placebo CPAP in adults with
OSAS.
2 University of
Witten/Herdecke, Faculty of
Health, Department of
Datacollectionandanalysis:Twoauthorsindependentlyassessedtrial
quality and extracted data. Parallel and crossover group trials were
analysed separately. A meta-analysis was carried out.
Nursing Science, Witten,
Germany
Results: Three parallel group and two cross-over randomised trials and
onecontrolledtrialwereincludedinvestigating296participants.Sample
sizesrangedfromn=13ton=102participants,agewas18to75years,
mean body mass index (BMI) 27.2 kg/m² to 37.1 kg/m², mean apnoe
hypopnoe index (AHI) 29.7 to 39.7 events per hour, mean dips >4% in
arterial oxygen saturation per hour of sleep 1 to 42.7 events. The
studies’ methodological quality varied. Follow-up ranged from 4 to 12
weeks.Variousendpointswereinvestigated.CPAPdidneitherinfluence
plasma insulin levels nor HOMA-index, adiponectin levels or HbA1c
value. One study reported a significant positive effect on the insulin
sensitivity index (1.68%/min, 95% CI 0.3 to 3.06).
Conclusion: This systematic review does not support the hypothesis
that OSAS independently influences glucose metabolism. Sufficiently
powered, long-term randomised controlled trials defining changes of
insulin resistance as primary endpoint are needed.
Keywords: Insulin resistance, continuous positive airway pressure,
obstructive sleep apnea, diabetes mellitus type 2, meta-analysis
Zusammenfassung
Hintergrund: Das Obstruktive Schlafapnoe-Syndrom (OSAS) ist durch
wiederholte Apnoen mit nachfolgenden Weckreaktionen während des
Schlafes gekennzeichnet. Es wird vermutet, dass obstruktive
SchlafapnoeneinenunabhängigenEinflussaufdenGlukosestoffwechsel
haben. Leitlinien empfehlen die kontinuierliche Überdruckbeatmung
(CPAP) zur Behandlung des OSAS.
Ziel:SystematischeSichtungundkritischeBeurteilungklinischerStudien
zu den Effekten einer CPAP-Beatmung auf Marker der Insulinresistenz
und des Glukosestoffwechsels.
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Review Article OPEN ACCESSSuchstrategie:DieSucheerfolgteindenDatenbankenMedline,Embase
unddemCochraneControlledTrialRegister.DerSuchzeitraumerstreck-
te sich bis Januar 2010.
Ein- und Ausschlusskriterien: Eingeschlossen wurden randomisiert-
kontrollierte und klinische kontrollierte Interventionsstudien, die eine
CPAP-TherapiemiteinerPlaceboCPAP-Therapieodereinernichtbehan-
delten Kontrollgruppe bei Patienten mit OSAS verglichen hatten.
Datensammlung und Analyse: Zwei Autoren extrahierten die Daten
unabhängig voneinander und beurteilten das Risiko für methodische
VerzerrungendereingeschlossenenStudien.InderMetaanalysewurden
Parallelgruppen-undCrossover-Studiengetrenntvoneinanderanalysiert.
Ergebnisse: Sechs Studien mit insgesamt 296 Probanden konnten
eingeschlossenwerden.DieStudienuntersuchen13bis102Teilnehmer
im Alter von 18 bis 75 Jahren. Der mittlere Body-Mass-Index (BMI) der
Studienteilnehmer beträgt 27,2 kg/m² bis 37,1 kg/m², der mittlere
Apnoe-Hypopnoe-Index (AHI) 29,7 bis 39,7 Ereignisse/Stunde, der
mittlere Abfall der arteriellen Sauerstoffsättigung >4% pro Stunde be-
trägt 1 bis 42,7 Ereignisse. Die Nachbeobachtungszeit der Studien
umfasst vier bis zwölf Wochen. Die methodische Qualität der Studien
ist unterschiedlich. Vier der fünf randomisiert-kontrollierten Studien
verwendeten ein doppelblindes Design; eine verdeckte Zuteilung zur
jeweiligenBehandlungsgruppeistlediglichinzweiStudienbeschrieben.
Eine Poweranalyse zur Fallzahlenkalkulation sowie ein Intention-to-
Treat-Analyse zur adäquaten Nachbeobachtung wurde in drei der fünf
Studien durchgeführt.
Das Poolen der Daten zeigte, dass eine CPAP-Therapie weder die Plas-
mainsulinspiegel, noch den Homaindex, die Adiponektinspiegel oder
die HbA1c-Werte beeinflusst. Eine Studie berichtete über einen signifi-
kantpositivenEffektderCPAP-TherapieaufdenInsulinsensitivitätsindex
(1,68%/min, 95% CI 0,3–3,06).
Schlussfolgerung: Das vorliegende systematische Review unterstützt
nicht die Hypothese, dass die CPAP-Therapie einen unabhängigen Ein-
fluss auf den Glukosestoffwechsel hat. Qualitativ hochwertige Studien
mit primärem Endpunkt Insulinresistenz, ausreichend langer Nachbe-
obachtungszeit und adäquater Stichprobe stehen aus.
Introduction
Obstructive Sleep Apnoea Syndrome (OSAS) is deemed
to be the most important respiratory dysfunction while
sleeping. OSAS is defined by the coexistence of an ob-
structive sleep hypopnoe or apnoea and excessive
sleepiness during the day [1]. Its symptoms result from
intermittent hypoxia and sleep fragmentation caused by
obstructive sleep apnoea [2]. OSAS is found in approxi-
mately 4% of middle-aged (30 to 60 years) men and 2%
of women [3], [4].
Continuous positive airway pressure (CPAP) is used as
first line treatment if symptoms and disease are severe.
The effectiveness of CPAP regarding elimination of ob-
structive sleep apnoea has been proven by a number of
randomised controlled studies [5], [6], [7], [8]. CPAP-
therapyislikelytoincreasequalityoflifeandtodecrease
fatigue during daytime in patients with intermediate and
severe OSAS [9].
TheassociationbetweenOSASanddiabetesmellitushas
beendiscussedcontroversially.In2008,aninternational
taskforce of the International Diabetes Federation (IDF)
requested that doctors, health care policy and persons
concernedshouldbealertedtothepotentiallinkbetween
these diseases and asked to intensify research in this
area[10].ExistingdatasuggestahigherOSASprevalence
amongst patients with diabetes mellitus [11], [12], [13],
[14]. It remains unclear whether this is a causal relation-
ship or due to coexistence of the two phenomena, be-
cause both diseases are commonly associated with
obesity.
Several possibilities regarding the postulated relation of
these two diseases are conceivable.
Intermittent hypoxia and arousals result in the activation
ofthesympatheticnervoussystemfollowedbytherelease
ofcontra-insulinhormoneslikeadrenalineandnoradren-
aline. Moreover, proteins known to induce insulin-resist-
ance like interleukin 6 and tumor necrosis factor alpha
are more frequently expressed [15], [16]. The accumula-
tion of oxidative stress causing or boosting an insulin-
resistance is also a matter of discussion [17], as well as
a possible relevant shift in the concentration of the
adipokines leptin, resistin and adiponectin. Finally, it is
assumed that OSAS induced disturbance of the
physiological sleep profile itself can cause an impaired
glucose tolerance [18].
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tioned above by the employment of CPAP-therapy would
lead to a reduced insulin-resistance or an improved
metabolicstatusforpeoplediagnosedwithdiabetestype
2. Studies with OSAS patients which have investigated
the impact of CPAP-therapy regarding insulin-sensitivity
and glucose metabolism have shown heterogeneous
results [19], [20], [21] [22], [23], [24], [25], [26], [27],
[28], [29], [30], [31], [32], [33], [34], [35], [36], [37],
[38], [39]. One of the reasons might be the difference in
length of follow up.
Availablereviewsonthissubjectarenon-systematic[10],
[40], [41], [42], neither defining inclusion criteria nor
critically appraising primary studies.
We therefore conducted a systematic review and a meta-
analysis following current methodological approaches
[43] aimed to assess the effects of CPAP-therapy on
markers of insulin-resistance and glucose metabolism.
Methods
Search strategy
A systematic literature search was performed using the
databases Medline (via PubMed), Embase, and the
Cochrane Controlled Trial Register. Abstract books of the
annual meetings of the German Diabetes Society
(DeutscheDiabetesGesellschaft)covering1999to2009
were screened. The search strategy followed the recom-
mendation of the Cochrane Handbook for Systematic
Reviews of Interventions 5.0.2 [43]. The overall search
strategy combined search terms for population (adults
with OSAS), therapy (CPAP, nasal CPAP (nCPAP), auto-
mated positve airway pressure (APAP)), and endpoints
(marker of insulin-resistance and glucose metabolism,
respectively). Results were limited to clinical controlled
studies (see Appendix for a detailed search strategy).
Selection of studies
Titlesandabstractsorfulltextsofidentifiedstudieswere
screened based on pre-defined inclusion criteria:
• Randomisedandnon-randomisedcontrolledinterven-
tionstudycomparingCPAP,nCPAPorAPAP(autoCPAP)
therapy with either placebo CPAP therapy or a non
treated control group
• OSASwasdiagnosedbyrespiratorypolysomnography,
age ≥18 years
• Primary or secondary endpoint defined as marker for
insulin-resistance (HOMA-index, plasma insulin level,
adiponectin, Hyperinsulinemic Euglycemic Glucose
Clamp trial) or glucose metabolism (HbA1c)
Exclusion criteria were:
• No control group
• Observationalstudy(cohortstudy,case-controlstudy),
review or duplicate
• Study having examined children and adolescents
• Study having examined patients with a central sleep
apnoea
• Studythatsolelyreliedonbloodglucoselevelsinorder
to determine insulin-resistance and glucose metabol-
ism
Figure 1 displays the flow of information through the re-
view.
Assessment of methodological quality
of included studies
Two authors (LH and RM) assessed each trial independ-
ently. Disagreement was solved by discussion and con-
sensus finding.
Forrandomisedcontrolledtrialsthefollowingcriteriawere
applied:
• Minimisation of selection bias: Adequate randomisa-
tion procedure and allocation concealment?
• Minimisation of performance bias: Were participants
and the investigators administering the treatment
blinded towards the intervention? Similar treatment
of study groups except intervention under investiga-
tion?
• Minimisation of detection bias: Blinding of outcome
assessors?
• For non-randomised controlled studies the following
criteria were applied:
• Minimisation of selection bias: Description of all rele-
vantpatientcharacteristics(age,BMI,AHI,etc.)?Study
groups comparable in terms of all relevant patient
characteristics?
• Minimisation of performance bias: Similar treatment
of study groups except intervention under investiga-
tion?
• Minimisation of detection bias: Adjustment for con-
founding?
• For both, randomised and non-randomised trials:
• Minimisation of attrition bias:
Follow-up of at least 80% of participants? •
Intention-to-treat (ITT) principle used? •
Data extraction
Patients’ clinical and demographic characteristics, out-
comes, administration way and duration of therapy, and
sideeffectswereobtainedindependentlybytworeviewers
using a standardised form and cross-checked for accur-
acy. Disagreement was solved by discussion and con-
sensus finding.
Extracted data were entered into the Review Manager
(RevMan) Version 5 Software.
Data analysis
A meta-analysis was carried out on the outcomes from
parallelgroupstudieswithafixed-effectmodelwithmean
differences (MD) as summary statistics for continuous
variables. For crossover studies, mean differences and
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standarderrorsforthemeandifferenceswerecalculated
and entered into RevMan as generic inverse variance
data. Heterogeneity was identified by visual inspection
of the forest plots and by using a standard χ
2-test with a
significance level of α=0.1, in view of the low power of
such tests. Heterogeneity was specifically examined with
I
2,whereI
2valuesof50%andmoreindicateasubstantial
level of heterogeneity.
Results
Results of the search
Our search strategy yielded a total of 926 studies; 920
papers were excluded.
Figure 1 displays the Flow Diagram.
Included studies
Thefinalsamplecomprisedsixstudieswithatotalof296
participants. Five studies [20], [21], [22], [23], [44] were
individuallyrandomised,one[45]wasanon-randomised
controlledtrial.Samplesizesrangedfromn=13ton=102
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(China,UnitedKingdom,andCanada)between1994and
2009.Onesmallstudy[21]investigatedmenandwomen;
all other studies investigated only men. Participants’ age
ranged from 18 to 75 years, mean BMI from 27.2 kg/m²
to 37.1 kg/m², mean AHI from 29.7 to 39.7 events per
hour, and mean dips >4% in arterial oxygen saturation
perhourofsleepfrom1to42.7events.Fivestudies[20],
[21], [22], [23], [44] stated OSAS diagnosed by polysom-
nographyasinclusioncriterion.Onlythenon-randomised
trial by Davies et al. [45] included patients without OSAS
in the control group. Four studies [20], [21], [23], [44]
excluded patients requiring urgent CPAP because of res-
piratory failure, driving or job issues and one study [22]
excluded patients with diabetes. The non-randomised
trial by Davies et al. [45] stated no inclusion or exclusion
criteria. Four trials [20], [22], [23], [44] compared CPAP
respectively APAP with placebo-CPAP while two studies
[21], [45] compared CPAP with no therapy. Insulin resist-
ance was assessed by fasting plasma insulin levels and
HOMA-Index,adiponectin,orKitt-insulin-sensitivityindex.
HbA1c was assessed in two studies [21], [23].
Studies’ characteristics are displayed in Table 1.
Risk of bias in included studies
Figure 2 indicates varying methodological quality of the
five included randomised controlled trials.
Figure 2: Methodological quality of the included randomised
controlled trials (n=5)*
Randomisation
Three studies seem to have used proper randomisation
[22], [23], [44] whereas the randomisation method has
not been described adequately in two studies [20], [21].
Adequate allocation of participants
Noneofthestudiesreportedabouttheallocationproced-
ure.
Blinding
Four out of five RCTs [20], [21], [23], [44] used double
blindingofCPAPrespirationinasubtherapeuticalmanner
(placebo CPAP), in the fifth RCT [21] the control group
did not receive treatment.
Standardized therapeutic approach
Three RCTs described methods to avoid unequal treat-
ment of study groups [22], [23], [44].
Follow-up
Three RCTs [20], [22], [44] used ITT analysis. The study
by West et al. [23] does not specify how data were ana-
lysed.Sincemorethan80%ofpatientsrandomisedhave
been analysed, adequate follow-up examination can be
assumed. The fifth study [21] does not describe exactly
the number of participants analysed.
Power analysis
Three RCTs [22], [23], [44] reported to have performed
a power analysis.
The non-randomised controlled study [45] lacks of a de-
taileddescription.Itremainsunclearwhetherthegroups
have been equally treated beyond the intervention in
question.Thedropoutrateis33%inbothgroups.Statistic
analysis is precisely represented.
Effects of intervention
Results of the meta-analysis
TojudgetheeffectofCPAPrespirationonmarkerofeither
insulin resistance or the glucose metabolism the mean
values of the study group differences where pooled and
assessed, respectively. Assuming that different authors
used different laboratory techniques to determine their
respective parameters, we also calculated standardised
mean values of the differences. The results however re-
mained the same and are therefore not displayed. A sig-
nificant influence of the CPAP respiration on marker of
either insulin resistance or the glucose metabolism was
neitherobservableintheresultsoftheindividual(Table2)
nor the pooled study. The study by Kohler et al. [20] was
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not included in the meta-analysis as this study reported
the median rather than mean values.
Statistical heterogeneity between studies was not appar-
ent.
Results of the crossover studies
A significant reduction in insulin levels (2 studies, n=61)
asaresultoftheCPAP-therapywasnotcalculated[mean
difference(MD)–2.95pmol/L,95%CI–20.39to14.50].
Likewise the HOMA-index (2 studies, n=61) did not
change significantly (MD –0.77, 95% CI –4.12 to 2.57).
Changes in HbA1c-values were analysed to evaluate the
glucose metabolism. A slight increase was calculated al-
thoughitdidnotreachstatisticalsignificance(MD0.04%,
95% CI –1.06 to 1.14) (MD 0.25 mmol/mol, 95% CI 6.57
to 7.07).
TheresultsofcrossoverstudiesaredisplayedinFigure3.
Results of the parallel group studies
Pooling of data from two studies did not reveal a signifi-
cant reduction in insulin levels (MD 0.24 pmol/L, 95%
CI –0.63 to 1.10). The non-randomised controlled study
by Davies et al. [45] did not show any influence of the
CPAP therapy on plasma insulin levels either. Due to
methodologicalshortcomingsthisstudywasnotincluded
in the meta-analysis.
Similar to the crossover studies the HOMA-index
(2 studies n=103) did not change (MD 0.07, 95%
CI –0.40 to 0.55).
Adiponectin levels have been assessed in two studies. A
significant change of this parameter could not be ob-
served.
Lam et al. [44] additionally determined the Kitt-insulin-
sensitivity index, which increased statistically significant
(MD 1.68%/min, 95% CI 0.3 to 3.06).
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Westetal.[23]didnotreportapositiveinfluenceofCPAP
respiration on the HbA1c-value (MD –0.12%, 95%
CI –0.84 to 0.60).
The results of parallel group studies are displayed in
Figure 4.
Discussion
Our meta-analysis demonstrated that CPAP-therapy
neither positively affects clinical markers of glucose
metabolism nor markers of insulin resistance.
Four studies have investigated plasma insulin level,
HOMA-indexandadiponectininordertoassesstheextent
ofinsulinresistance.Noneofthestudiesfoundbeneficial
effects. A single study [44] describes a significant in-
creaseoftheinsulinsensitivityindex.Theauthorssuggest
apositiveinfluenceofCPAP-therapyoninsulinresistance.
However, no changes in the HOMA-index and plasma in-
sulin level were found. Although considered as gold
standard, the hyperinsulinemic-euglycemic clamp tech-
niquehasnotbeenusedforassessmentofinsulinresist-
ance. Nevertheless, the HOMA-index and the plasma in-
sulin level are also well accepted methods [46]. Two
groups[21],[23]examinedHbA1c-valuestoevaluatethe
influence of CPAP on glucose metabolism. A significant
reduction could not be found.
Non-controlled trials suggest that CPAP-therapy has
beneficial effects towards the improving of glucose
metabolism [28], [29], [30], [32], [36], [37], [47]. Since
our meta-analysis did not confirm these findings, this is
another piece of evidence demonstrating the discrepan-
ciesinresultsandconclusionsbetweennon-randomised
and randomised trials.
The method to determine insulin resistance importantly
influences the studies’ results. Harsch et al. [32] found
asignificantreductionofinsulinresistanceinn=40OSAS
patients studying the effect of CPAP-respiration in a non-
controlledsetting.Thehyperinsulinemic-euglycemicclamp
technique was used to determine insulin resistance. The
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a venous indwelling catheter, repeated blood testing and
prolongedimmobilisation.Thismightleadtoanactivation
of the sympathetic nervous system which in turn could
increase insulin resistance. Changes in the magnitude
of insulin resistance before and after the deployment of
aCPAP-therapycouldthereforeonlyresultfromtheadap-
tion to examination conditions [48].
It is of particular interest whether OSAS independently
influences insulin resistance and glucose metabolism or
whether an association solely coexists in the presence
of obesity. Four of the five trials [20], [21], [22], [23]
analysedinourreviewinvestigatedparticipantswithBMI
between 35.8 and 37.1 kg/m². There was no evidence
for an independent CPAP-therapy related effect on the
glucose metabolism. Ip et al. [49] already suggested
obesity as major determinant of insulin resistance while
OSAS was judged to have a marginal influence.
Some experts argue that patients with high AHI may be-
nefit more by CPAP concerning markers of insulin resist-
ance or glucose metabolism. However, the results gener-
ated by the present review are independent of the
severity of OSAS and populations’ characteristics. It re-
mains unclear whether the results can be extrapolated
to women since only four women were included in the
review’s sample.
Compliance with CPAP was on average good varying
between 4.7 and 5.5 hours per night in the three trials
explicitly reporting on this issue [20], [21], [44]. Thus,
lack of compliance is unlikely to explain our results. In
thestudybyCoughlinetal.[22]goodtherapycompliance
(>3.5 hrs per night) did not lead to better outcome. West
et al. [44] did not find a significant correlation between
the length of CPAP use and glucose metabolism.
Strengths and limitations of the
review
The strength of our meta-analysis is the inclusion of ran-
domised controlled trials only.
However, the primary studies are likely to be affected by
importantmethodologicalflaws.Threeoffiverandomised
studies [20], [21], [22] did not report predefinition of the
markers of insulin resistance and glucose metabolism
asprimaryendpoints,twostudies[20],[21]didnotreport
a power analysis.
Agreement on a set of meaningful endpoints seems to
be important for future randomised controlled trials in-
vestigating the effects of CPAP on diabetes outcomes.
Designandreportingoftrialsshouldmeetthecontempor-
arystandardsoftheCONSORTstatement[50].Unwanted
side effects of CPAP-respiration should be carefully as-
sessed. It is quite unacceptable that none of the six
publications included in our review reported on adverse
effects. Beyond that, four out of six publications [20],
[21],[23],[45]didnotpresentparticipants’concomitant
medication. However, information about participants’
prescribed medication is indispensable in this field of
diabetes research.
We could not rule out a language bias of our systematic
review since only English or German language publica-
tions were considered for inclusion. Two Chinese public-
ations [24], [34] were excluded since the English full text
was not accessible. However, the English abstract indi-
cated that these publications would not have influenced
our results.
We could also not exclude a publication bias. Funnel plot
statistic was not feasible since the number of included
studies was too small.
Conclusions
In summary, an independent influence of OSAS on glu-
cose metabolism could not be confirmed. Thus, CPAP-
therapy indication should be placed independently of
these parameters especially for people suffering from
diabetes.
The longest follow-up period of the included studies was
12 weeks only. Unfortunately, currently ongoing trials did
notplanlongerobservationperiods[51],[52],[53].Since
OSAS is a chronic disease a possible gradual reduction
ofinsulinresistanceorimprovementofglucosemetabol-
ismthroughCPAPtreatmentlastingseveralmonthscould
not be excluded. This issue remains to be addressed in
long-termrandomisedcontrolledtrials.Thesetrialsshould
be sufficiently powered, include both sexes, and define
changes of insulin resistance as primary endpoint. In the
end, clinical efficacy remains to be proven in high quality
trials investigating important outcomes such as diabetic
complications and patient-reported outcomes.
Appendix: Search strategy
PubMed
1. exp. Sleep Apnea Syndromes
2. sas. tw
3. sleep apn* syndromes.tw
4. osa.tw
5. obstructive sleep apn*.tw
6. osas.tw
7. obstructive sleep apn* syndrome.tw
8. sahs.tw
9. sleep apn* / hypopn* syndrome.tw
10. apn*.tw
11. hypopn*.tw
12. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
or #10 or #11
13. continuous positive airway pressure.sh
14. positive-pressure respiration.sh
15. cpap.tw
16. continuous positive airway pressure.tw
17. ncpap.tw
18. nasal continuous positive airway pressure.tw
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20. continuous distending pressure.tw
21. cdap.tw
22. distending pressure.tw
23. continuous positive transpulmonary pressure.tw
24. continuous transpulmonary pressure.tw
25. #13 or #14 or #15 or #16 or #17 or #18 or #19 or
#20 or #21 or #22 or #23 or #24
26. exp. glucose metabolism disorder
27. diabetes mellitus.tw
28. diabetes.tw
29. iddm.tw
30. niddm.tw
31. mody.tw
32. glucose intolerance.sh
33. glucose toleran*.tw
34. reduced glucose toleran*.tw
35. reduced glucose metabolism.tw
36. glucose.tw
37. blood gluose.tw
38. exp. insulin resistance
39. insulin Resistance.tw
40. insulin sensitivity.tw
41. reduced insulin secret*.tw
42. impaired insulin secret*.tw
43. hemoglobin A, glycosylated.sh
44. HbA1c.tw
45. hemoglobin A1c.tw
46. #26 or #27 or #28 or #29 or #30 or #31 or #32 or
#33 or #34 or #35 or #36 or #37 or #38 or #39 or
#40 or #41 or #42 or #43 or #44 or #45
47. exp. clinical trial
48. prospective studies.sh
49. randomized controlled trials.sh
50. randomized controlled trial.pt
51. clinical trial.pt
52. controlled clinical trial.pt
53. meta-analysis.sh
54. exp. Review
55. systematic review.tw
56. #47 or #48 or #49 or #50 or #51 or #52 or #53 or
#54 or #55
57. #12 and #25 and #46 and #56
• tw = denotes a textword
• exp = denotes a exploded Medical Subject Heading
(MeSH) term
• sh = denotes a Medical Subject Heading (MeSH) term
• pt = denotes a Publication Type term
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